Many therapies have been used to treat PRCA, including erythropoietin (EPO), desensitization apheresis (plasma exchange, rituximab, and etc.), immunosuppression, and donor leukocyte infusion (DLI), but the efficacy is different and unsatisfactory (2, 9, 10). This evidence concerns the gene EPO and pure red-cell aplasia.